logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9827216 B1

PDFFull Text
Date of Patent:
Nov. 28, 2017

Filed:

Sep. 11, 2009

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

Applicants:

Eduardo Schiffrin, Crissier, CH;

Kevin Burke Miller, Minneapolis, MN (US);

Dominique Brassart, Chavannes-Pres-Renes, CH;

Olivier Jacques Lantz, Paris, FR;

Sebastian Diego Amigorena, Paris, FR;

Inventors:

Eduardo Schiffrin, Crissier, CH;

Kevin Burke Miller, Minneapolis, MN (US);

Dominique Brassart, Chavannes-Pres-Renes, CH;

Olivier Jacques Lantz, Paris, FR;

Sebastian Diego Amigorena, Paris, FR;

Assignees:

Nestec S.A., Vevey, CH;

Institut Curie, Paris, FR;

Attorney:

K&L Gates LLP

Primary Examiner:

Brian Gangle

Int. Cl.
CPC ...
A61K 31/20 (2006.01); A61K 31/195 (2006.01); A61K 31/7088 (2006.01); A61K 35/747 (2015.01); A61K 38/40 (2006.01); A61K 38/01 (2006.01); A61K 35/745 (2015.01); A61K 38/17 (2006.01); A61K 33/00 (2006.01); A23L 33/00 (2016.01); A23L 33/13 (2016.01); A23L 33/135 (2016.01); A23L 33/175 (2016.01); A23L 33/19 (2016.01);
U.S. Cl.
CPC ...
A61K 31/195 (2013.01); A23L 33/13 (2016.08); A23L 33/135 (2016.08); A23L 33/175 (2016.08); A23L 33/19 (2016.08); A23L 33/40 (2016.08); A61K 31/20 (2013.01); A61K 31/7088 (2013.01); A61K 33/00 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61K 38/018 (2013.01); A61K 38/1783 (2013.01); A61K 38/40 (2013.01); A23V 2002/00 (2013.01);
Abstract

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Find Patent Forward Citations

Loading…